There’s a first time for everything, and now is the time for Enveric Biosciences to submit its first-ever IND to the FDA.
After forgoing a Phase 1 in Australia and deciding to out-license that asset, Enveric now finds itself facing its first IND submission. This time, they’re seeking the OK for EB-003, a novel neuroplastogen designed to be a fast-acting, well-tolerated, and non-hallucinogenic therapy for those with post-traumatic stress disorder (PTSD), treatment-resistant depression, and generalized anxiety.
